Researcher
Christine Desmedt
- Disciplines:Oncology
Affiliations
- Laboratory for Translational Breast Cancer Research (Division)
Responsible
From1 Oct 2018 → Today - Laboratory for Translational Breast Cancer Research (Division)
Member
From1 Oct 2018 → Today - Department of Oncology (Department)
Member
From1 Oct 2018 → 25 Dec 2018
Projects
1 - 10 of 23
- Atlas of therapeutic targets in metastatic breast cancer.From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- MetLob: A post-mortem tissue donation study dedicated to Metastatic Lobular breast cancerFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Impact of adiposity and lifestyle on breast cancer biology and treatment response.From7 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Histopathological heterogeneity of metastatic breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical and molecular heterogeneity of triple-negative breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of the tumor microenvironment of breast cancer metastasesFrom11 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- LIQUIDEVO: Unravelling breast cancer heterogeneity, progression and treatment resistance in the context of a rapid post-mortem institutional tissue donation program using phylogenetic reconstruction algorithms and an Open Science approach.From1 Oct 2021 → TodayFunding: FWO senior postdoctoral fellowship
- Facing Adiposity in personalizing Treatment of Breast Cancer PatientsFrom1 Mar 2021 → TodayFunding: H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
- Clinical, experimental and molecular characterization of liver metastases from breast cancer patients.From1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
Publications
21 - 30 of 115
- Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?(2023)
Authors: Karen Van Baelen, Christine Desmedt, Hans Wildiers, Patrick Neven
Pages: 269 - Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding(2023)
Authors: Maxim De Schepper, Tatjana Geukens, Stefaan Soenen, Christine Desmedt, Colinda Scheele, Anna Sablina, Max Mazzone
- Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer (vol 33, pg 769, 2022)(2023)
Authors: François Richard, Chantal Van Ongeval, Maxim De Schepper, Ann Smeets, Hans Wildiers, Patrick Neven, Christine Desmedt
Pages: 326 - 326 - Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER plus ) breast cancer: a retrospective analysis of the SOLE trial(2023)
Authors: François Richard, Beppe Floris, Patrick Neven, Christine Desmedt
- Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2-invasive lobular breast cancer(2023)
Authors: Karen Van Baelen, François Richard, Maxim De Schepper, Tatjana Geukens, Hans Wildiers, Ines Nevelsteen, Beppe Floris, Patrick Neven, Christine Desmedt
- Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial(2023)
Authors: Christine Desmedt, François Richard, Karen Van Baelen
- Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases(2023)
Authors: Sigrid Hatse, Anke Vandekeere, Yentl Lambrechts, François Richard, Annouschka Laenen, Patrick Neven, Ines Nevelsteen, Beppe Floris, Christine Desmedt, Sarah-Maria Fendt, et al.
- Challenging the current 1-10% cut-off for defining Estrogen Receptor Low Positive grade 2-3 Estrogen Receptor positive, Human Epidermal growth factor Receptor 2 negative early breast cancer(2023)
Authors: Beppe Floris, Christine Desmedt, Ines Nevelsteen, Hans Wildiers, Patrick Neven
- Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score(2023)
Authors: Patrick Neven, Annouschka Laenen, Hans Wildiers, Ines Nevelsteen, Sileny Han, Eva Oldenburger, Christine Desmedt
- Stromal tumor infiltrating lymphocytes and pathological complete response in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy(2023)
Authors: Maxim De Schepper, François Richard, Hans Wildiers, Ines Nevelsteen, Patrick Neven, Beppe Floris, Christine Desmedt